Chapter 63 Hypercoagulable States
Table 63-3 Causes of Acquired Antithrombin Deficiency
Decreased Synthesis | Increased Consumption | Enhanced Clearance |
---|---|---|
Hepatic cirrhosis | Major surgery | Heparin |
Severe liver disease | Acute thrombosis | Nephrotic syndrome |
l-asparaginase | Disseminated intravascular coagulation | |
Severe sepsis | ||
Multiple trauma | ||
Malignancy | ||
Prolonged extracorporeal circulation |

Figure 63-1 THROMBOSIS THRESHOLD.
(From Anderson JA, Weitz JI: Hypercoagulability and uncommon vascular diseases. In Jaff MR, White CJ, editors: Vascular disease: Diagnostic and therapeutic approaches, Minneapolis, Minn, 2011, Cardiotext Publishing.)

Figure 63-2 PROTEIN C PATHWAY.
(From Anderson JA, Weitz JI: Hypercoagulability and uncommon vascular diseases. In Jaff MR, White CJ, editors: Vascular disease: Diagnostic and therapeutic approaches, Minneapolis, Minn, 2011, Cardiotext Publishing.)
Table 63-4 Types of Inherited Protein C Deficiency
Type | Antigen | Activity |
---|---|---|
I | Low | Low |
II | Normal | Low |
Table 63-6 Features of Heparin-Induced Thrombocytopenia
Feature | Details |
---|---|
Thrombocytopenia | Platelet count of 100,000/µl or less or a decrease in platelet count of 50% or more |
Timing | Platelet count falls 5 to 10 days after starting heparin |
Type of heparin | More common with unfractionated heparin than LMWH |
Type of patient | More common in surgical patients than medical patients; more common in women than in men |
Thrombosis | Venous thrombosis more common than arterial thrombosis |
Routine Investigations to Evaluate a Patient With (Venous) Thrombosis
Test | Abnormality | Diagnostic Information |
---|---|---|
Complete blood count | Elevated hematocrit Increased white count Increased platelet count Leukopenia Thrombocytopenia |
Myeloproliferative disorder (e.g., essential thrombocythemia, polycythemia vera); may be found in paroxysmal nocturnal hemoglobinuria; if associated with heparin administration, consider heparin-induced thrombocytopenia |
Blood film | Leukoerythroblastic film | Underlying neoplasm invading bone marrow |
Liver function tests | Abnormal tests | May point to malignancy |
Renal function | Impaired renal function | Assess prior to anticoagulation with heparin or LMWH |
Urinalysis | Proteinuria | Nephrotic syndrome; may be associated with venous thromboembolism or renal vein thrombosis |
PT and aPTT | Prolonged PT and aPTT | To enable safe anticoagulation to proceed if required Need to exclude lupus anticoagulant |
When to Perform a Thrombophilia Screen
Clinical Scenario
• First episode of unprovoked venous thromboembolism in individuals younger than 40 years of age
• Thrombosis in an unusual site (e.g., cerebral or mesenteric thrombosis)
• Two or more first-degree relatives with unprovoked thrombosis
• Females with a history of more than one second-trimester pregnancy loss or intrauterine death
Essential Tests for Thrombophilia Screening
Functional assay for antithrombin: (with heparin to detect type II defects)
Functional assay for protein C
Functional assay for protein S: (immune assays for total and free protein S)
APC resistance assay: with genetic test for factor VLeiden for confirmation of abnormal results
Clinical Scenarios That Merit Long-Term Anticoagulation*
• Two or more unprovoked venous thrombotic events in less than 2 years, or within a relatively short space of time
• A single unprovoked thrombosis in an individual with antithrombin deficiency, APS, dual heterozygosity for the factor VLeiden and FIIG20210A gene mutations, or homozygosity for these mutations
• A single unprovoked massive or submassive pulmonary embolism
• An episode of venous thrombosis in a patient with active malignancy